Revolution Medicines (NASDAQ:RVMD) Given New $40.00 Price Target at Oppenheimer
Revolution Medicines (NASDAQ:RVMD – Free Report) had its price objective upped by Oppenheimer from $35.00 to $40.00 in a research note issued to investors on Wednesday, Marketbeat.com reports. Oppenheimer currently has an outperform rating on the stock. Several other equities analysts also recently issued reports on RVMD. HC Wainwright reissued a buy rating and set […]